Coherus Oncology, Inc. (NASDAQ: CHRS) unveiled plans for a public stock offering on February 12, 2026, signaling its commitment to accelerate growth in the competitive oncology market. The California-based company seeks to capitalize on its approved therapies and strengthen its clinical pipeline,